title: Uridine function in the central nervous system.
abstract: In the adult nervous system, the major source of nucleotide synthesis is the salvage pathway. Uridine is the major form of pyrimidine nucleosides taken up by the brain. Uridine is phosphorylated to nucleotides, which are used for DNA and RNA synthesis as well as for the synthesis of membrane constituents and glycosylation. Uridine nucleotides and UDP-sugars may be released from neuronal and glial cells. Plasmamembrane receptors of 7 transmembrane domains have been identified that recognize UTP, UDP, and UDP-sugar conjugates. These receptors are called P2Y2 and P2Y4, P2Y6, and P2Y14 receptors, respectively. In addition, binding sites for uridine itself have also been suggested. Furthermore, uridine administration had sleep-promoting and anti-epileptic actions, improved memory function and affected neuronal plasticity. Information only starts to be accumulating on potential mechanisms of these uridine actions. Some data are available on the topographical distribution of pyrimidine receptors and binding sites in the brain, however, their exact role in neuronal functions is not established yet. There is also a scarcity of data regarding the brain distribution of other components of the pyrimidine metabolism although site specific functions exerted by their receptors might require different metabolic support. Despite the gaps in our knowledge on the neuronal functions of pyrimidine nucleosides, their therapeutic utilization is appealing. They have been suggested for the treatment of epileptic and neurodegenerative diseases as neuroprotective agents. In addition, the development of traditional drugs acting specifically on pyrimidine receptor subtypes is also promising as a new direction to treat neurological disorders.
authors.affiliation: Neuromorphological and Neuroendocrine Research Laboratory, Department of Anatomy, Histology and Embryology,Semmelweis University and the Hungarian Academy of Sciences, H-1094 Budapest, Hungary. dobolyi@ana.sote.hu
authors.forename: Arpád
authors.initials: A
authors.lastname: Dobolyi
authors.forename: Gábor
authors.initials: G
authors.lastname: Juhász
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Kovács
authors.forename: Julianna
authors.initials: J
authors.lastname: Kardos
mesh_terms: D000328:Adult; D000818:Animals; D002490:Central Nervous System / Q000502:physiology; D004827:Epilepsy / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008568:Memory / Q000187:drug effects; D051379:Mice; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000503:physiopathology; D009457:Neuroglia / Q000378:metabolism*; D009473:Neuronal Plasticity; D009474:Neurons / Q000166:cytology / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000378:metabolism / Q000494:pharmacology; D058910:Purinergic P2 Receptor Agonists / Q000494:pharmacology; D058919:Purinergic P2 Receptor Antagonists / Q000494:pharmacology; D051381:Rats; D058470:Receptors, Purinergic P2Y / Q000378:metabolism*; D012890:Sleep / Q000187:drug effects; D014500:Uracil Nucleotides / Q000378:metabolism*; D014529:Uridine / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology*
chemical_list: D018696:Neuroprotective Agents; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D058470:Receptors, Purinergic P2Y; D014500:Uracil Nucleotides; D014529:Uridine